J P Morgan Chase & Co set a GBX 4,500 ($59.79) target price on AstraZeneca plc (LON:AZN) in a research report report published on Wednesday morning. The firm currently has a neutral rating on the biopharmaceutical company’s stock.
A number of other brokerages also recently issued reports on AZN. Morgan Stanley reaffirmed an overweight rating and set a GBX 5,600 ($74.41) price target on shares of AstraZeneca plc in a report on Friday, June 23rd. UBS AG set a GBX 5,150 ($68.43) price target on shares of AstraZeneca plc and gave the company a neutral rating in a report on Tuesday, June 27th. Shore Capital reaffirmed a hold rating on shares of AstraZeneca plc in a report on Wednesday, June 21st. Kepler Capital Markets reaffirmed a buy rating and set a GBX 5,500 ($73.08) price target on shares of AstraZeneca plc in a report on Thursday, July 13th. Finally, Liberum Capital reaffirmed a buy rating and set a GBX 5,500 ($73.08) price target on shares of AstraZeneca plc in a report on Thursday, July 13th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of GBX 5,172.64 ($68.73).
AstraZeneca plc (LON AZN) opened at 5162.00 on Wednesday. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00. The stock’s market capitalization is GBX 65.35 billion. The firm has a 50-day moving average of GBX 4,923.51 and a 200-day moving average of GBX 4,914.37.
In related news, insider Nazneen Rahman acquired 39 shares of AstraZeneca plc stock in a transaction dated Thursday, July 27th. The shares were purchased at an average price of GBX 4,370 ($58.07) per share, for a total transaction of £1,704.30 ($2,264.55).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.